2023 World Conference on Lung Cancer (Posters)-EP13.03. Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study

EP13.03. Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study - PDF(Slides)

Back to course

Pdf Summary

A recent study conducted in China analyzed the correlation between immune-related adverse events (irAEs) and the efficacy of PD-1/PD-L1 inhibitors in patients with small cell lung cancer (SCLC). The study included 219 SCLC patients who received PD-1/PD-L1 inhibitors between January 2008 and June 2022.<br /><br />The findings of the study suggest that the presence of irAEs predicts better clinical outcomes in SCLC patients receiving PD-1/PD-L1 inhibitors. Patients who developed multi-system irAEs had improved survival compared to those who developed single-system irAEs.<br /><br />The most common irAEs observed were endocrine system toxicity, skin reactions, and immune pneumonia. Hypothyroidism combined with pneumonia and hypothyroidism combined with skin rash were the most common multi-system irAEs. The time to first irAE was around 2.3 months.<br /><br />The study also found that longer PD-1/PD-L1 inhibitor duration was a risk factor for the development of irAEs. Patients in the irAE group had a longer median progression-free survival (PFS) and overall survival (OS) compared to those in the no-irAE group. Among the different irAEs, thyroid dysfunction was the most powerful indicator for improved PFS and OS.<br /><br />When the occurrence of irAEs was analyzed as a time-dependent covariate, it was associated with a significant improvement in PFS but not OS. Furthermore, the occurrence of multi-system irAEs was associated with longer PFS and OS.<br /><br />Overall, the study suggests that the development of irAEs is associated with better clinical benefit in SCLC patients treated with PD-1/PD-L1 inhibitors. The findings highlight the importance of monitoring and managing irAEs in this patient population.

Asset Subtitle

Yuping Sun

Meta Tag

Speaker Yuping Sun

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

China

irAEs

PD-1/PD-L1 inhibitors

SCLC

clinical outcomes

multi-system irAEs

endocrine system toxicity

skin reactions

hypothyroidism

progression-free survival